The District Court of The Hague declares the Dutch part of Bayer’s European Patent covering Anti-TNF alpha human monoclonal antibodies invalid. The Court considers that the patent covers high affinity antibodies. However, the Court finds that such type of antibodies is not sufficiently disclosed in the patent specification, and therefore invalidates the patent as a…

The District Court of The Hague, Administrative Division, considers the granting of an SPC to a patent proprietor that does not possess a market authorization for a medicine protected by the patent, not to be in conformity with the purpose of the SPC Regulation on medicinal products (Regulation (EC) No. 469/2009). A full summary of…

The District Court of The Hague finds that the generic products of the defendants fall under the scope of protection of both of Mundipharma’s patents, which are related to controlled release oxycodone formulations. According to the District Court, the scope of protection of the patents is not limited to products wherein all oxycodone is within…